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Abstract
Seasonal and pandemic influenza remains a constant threat. While standard influenza vaccines have great utility, the
need for improved vaccine technologies have been brought to light by the 2009 swine flu pandemic, highly
pathogenic avian influenza infections, and the most recent early and widespread influenza activity. Species C
adenoviruses based on serotype 5 (AD5) are potent vehicles for gene-based vaccination. While potent, most humans
are already immune to this virus. In this study, low seroprevalent species D adenoviruses Ad26, 28, and 48 were
cloned and modified to express the influenza virus A/PR/8/34 hemagglutinin gene for vaccine studies. When studied
in vivo, these species D Ad vectors performed quite differently as compared to species C Ad vectors depending on
the route of immunization. By intramuscular injection, species D vaccines were markedly weaker than species C
vaccines. In contrast, the species D vaccines were equally efficient as species C when delivered mucosally by the
intranasal route. Intranasal adenovirus vaccine doses as low as 108 virus particles per mouse induced complete
protection against a stringent lethal challenge dose of influenza. These data support translation of species D
adenoviruses as mucosal vaccines and highlight the fundamental effects of differences in virus tropism on vaccine
applications.
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Introduction
Influenza virus infections impose a significant burden on our
society. Annually, 5-15% of the world’s population is affected
by epidemics and have upper respiratory tract infections, 3 to 5
million have severe illness and 250,000 to 500,000 cases result
in death [1]. In the U.S.A. seasonal influenza affects up to 20%
of the population, results in 200,000 hospitalizations and
approximately 37,000 deaths each year. The World Health
Organization (WHO) states, "Influenza rapidly spreads around
the world in seasonal epidemics and imposes a considerable
economic burden in the form of hospital and other health care
costs and lost productivity. In the United States of America, it is
estimated that influenza epidemics cost up to $167 billion per
year [2]”.
While these seasonal epidemics are certainly of concern,
pandemic influenza outbreaks are of substantially higher
concern. During the past century there have been several
severe pandemics [1]. In 1918-1919, an H1N1 known as the
Spanish Flu caused the world’s largest influenza pandemic
killing 20-40 million people. In 1957, the Asian flu caused by an
H2N2 virus resulted in ~1.5 million deaths and in 1968, the
Hong Kong flu caused by an H3N2 influenza resulted in ~1
million deaths.
Trivalent Inactivated Vaccine (TIV) is the standard for
influenza vaccination and has protected millions of humans
from influenza morbidity and mortality. While somewhat
effective, TIV has limitations that support the development of
alternate vaccine platforms. Some of the limitations to using
TIV include the following: The use of embryonated eggs is a
fundamental problem with this vaccine platform. A large
fraction of humans are allergic to egg ovalbumin and cannot
take this vaccine. Generating influenza vaccines in eggs is time
consuming and labor intensive and relies on the availability of
embryonated eggs. TIV only provides short-term immunity [3]
and this immunity is highly strain specific [4,5]. Intramuscular
delivery does not stimulate high levels of the secretory IgA that
is thought to be more reactive against heterologous viruses
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(12,26,27,31,38). Importantly, the TIV vaccine also fails to
induce cross-protective cellular immunity [5–9]. Finally, one of
the most fundamental problem relates to the requirement that
human influenza virus be adapted to grow in chicken eggs
before a vaccine can be produced [10–14]. A perfect example
of this problem was during the 2009 H1N1 swine flu pandemic.
In this case, delivery of the 2009 monovalent inactivated
vaccine (MIV) was delayed by months due to slow growth of
this virus during egg-based vaccine production [15]. In addition
to these limitations a recent study of the TIV vaccine efficacy
showed that it was only effective 59% of the time [16].
FluMist is a live-attenuated cold-adapted influenza virus
platform that is administered intranasally. While this new
platform has the advantage of being needle-free and induces a
low level of cellular immunity it still has many limitations that
support the study of alternative vaccine platforms. These
limitations include cost, egg allergies, the vaccine is restricted
to certain age groups, priming requires two doses of vaccine, it
cannot be administered to immunocompromised patients, and,
importantly, studies have shown that the protective immune
responses induced by Flumist decline more rapidly than the
TIV [17–19] indicating a need for new influenza vaccine
technologies.
Adenoviruses are non-enveloped linear double-stranded
DNA viruses. Human adenoviruses have been classified into
57 unique types that are defined into 7 species (A-G) [20].
Adenoviruses are attractive viral vectors for use as vaccines,
since viral genes can be readily removed and replaced with
antigen genes from a pathogen.
One of the most studied and used Ad vectors was derived
from the species C adenovirus type 5 (Ad5). Unfortunately,
epidemiological studies show that Ad5 is one of the most
seroprevalent of these human viruses and is therefore more
likely to be less effective in human vaccinees [21–23]. Beyond
Ad5, there are a number of human adenoviruses that are
markedly less seroprevalent in the population. Given that these
are less likely to be neutralized in humans during vaccination,
we and others have tested them as alternatives to Ad5 [24]. In
this work, we cloned the genomes from three low seroprevalent
species D adenoviruses [21,25,26] and modified these to carry
antigens from influenza. We have compared these vaccines to
the Ad5 benchmark vaccine by intramuscular and intranasal
routes of vaccination to protect mice from a stringent lethal
challenge by influenza virus.
Results
Protection Against Heterologous Influenza by
Traditional Influenza Vaccine Versus Ad5 Gene-based
Vaccine
Trivalent Inactivated Vaccine (TIV) is a protein-based
vaccine and is the standard for seasonal influenza vaccination.
The 2009 monovalent inactivated vaccine (MIV) is also a
protein-based vaccine, but in this case directed against only
one strain of influenza (A/CA/07/09) [27].
To assess the utility of Ad vectored vaccines against
influenza, we compared a standard replication-defective Ad5
(Ad5-RD) expressing the HA from the 2009 H1N1 swine flu to a
traditional protein-based MIV vaccine. In 2009-2010, human
vaccinees received 15 µg doses of the 2009 MIV by the i.m.
route. For a 70 kg human, this corresponds to approximately
0.2 µg/kg doses. Mice were immunized with 4, 40, or 1,500 ng
of MIV by the i.m. route, which corresponds approximately to
0.2, 2.0, and 75 µg/kg doses. Parallel groups of mice were
immunized with 10-fold dilutions of Ad5 expressing codon-
optimized hemagglutinin (HA) from a 2009 H1N1 strain A/TX/
05/09 (Ad5-TX). The MIV and Ad5-TX vaccines both contain
isolates from the 2009 swine flu pandemic. The HA protein
sequences of these two isolates are 99.5% identical. The
doses ranged from 1010-106 virus particles (vp)/mouse. These
doses correspond to delivery of 0.75 to 7500 ng of Ad protein.
It should be noted, that this protein concentration is made up of
Ad virus proteins and not influenza protein antigens, but is
provided simply for comparison to the MIV vaccine.
BALB/c mice were immunized intramuscularly with varying
doses of the two vaccines in order to titrate the level of
protection induced by the two vaccine platforms (Figure 1). The
mice were then challenged intranasally 3 weeks later with 100
MLD50 of mouse-adapted influenza A/PR/8/34 to model a virus
challenge heterologous to both of the vaccines. Under these
conditions, the MIV vaccine did not provide any detectable
cross-protection against A/PR/8/34 as assessed by weight loss
and survival (Figure 1A). In contrast, the Ad5-TX vaccine
reduced weight loss at doses ≥ 108 vp/mouse and increased
survival at all doses (Figure 1B). A dose as low as 108 vp/
mouse of Ad5-TX resulted in 100% survival as compared to 0%
survival at the highest dose of MIV. Higher doses of Ad5-TX
(1010) protected mice completely against both weight loss and
death. Cross protection by Ad expressed HA genes had been
observed previously. Ad5 expressing full-length A/PR/8/34 HA
was shown to provide cross-protection against A/FM/1/47 and
A/CA/04/09 [28].
Generation of Lower Seroprevalent Ad Vaccines
against Influenza
Ad5 is a potent vaccine vector. However, most humans are
immune to the virus and this immunity would likely blunt
vaccine efficacy. Given this, we cloned the genome for Ad6.
Ad6 is a lower seroprevalent species C virus (Figure S1)
similar to Ad5 [29]. We also cloned three low seroprevalent
species D viruses, Ad26, 28, and 48 (Figures S2-S4). These
viruses not only differ in terms of human immunity, but vary in
tropism. Species C viruses use the coxsackie and adenovirus
receptor (CAR) and αv integrins and species D viruses use
integrins, CD46, and/or sialic acid as receptors for virus entry.
Each viral genome was cloned and replication-competent or
replication-defective Ad vaccines were constructed by
replacement of the E3 or E1 regions with an expression
cassettes for the influenza hemagglutinin (HA) gene.
Comparison of Immunity Against Influenza Induced By
Species C And D Ad Vaccines by Intramuscular
Immunization
We compared the two species C vaccines (Ad5 and Ad6) to
three species D vaccines (Ad26, Ad28 and Ad48) as
replication-competent vectors with intact E1 genes and HA
Species D Adenovirus Flu Vaccines
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replacing the E3 domain. An in vitro analysis of HA expression
by the vectors showed that HA was expressed in a similar
amount regardless of Adenovirus type or location of the
transgene (Figure S7). BALB/c mice were immunized
intramuscularly with 1010 vp/mouse of the species C and D Ad
vaccines. Three weeks after immunization the mice were
challenged intranasally with 100 MLD50 of influenza A/PR/8/34
(Figure 2). Under these conditions, both of the species C Ad
vaccines mediated significant reductions in weight loss and
100% survival (Figure 2A). In contrast, species D Ad28
provided little protection (Figure 2B). Ad48 induced greater
levels of protection than Ad28. However, only Ad26 vaccine
mediated 100% survival. Even though Ad26 mice survived,
there was still significant weight loss and disease in the
animals as compared to Ad5 and Ad6. Statistical analyses
showed that the Ad28 vaccinated mice had significantly higher
mortality rate than either species C Ad vaccines (p = <0.05). A
hemagglutination inhibition (HI) assay on sera from i.m.
immunized mice showed weaker anti-influenza immune
responses in species D Ad vaccinated mice (Figure 2C).
Statistical analyses showed that both Ad5 and Ad6 induced
significantly higher HI titers than Ad48 (p = <0.05).
Comparison of Species C And D Ad Vaccines By
Intranasal Immunization
BALB/c mice were immunized intranasally with 1010 vp/
mouse. This route stimulates the mucosa in a manner similar to
that of the licensed FluMist vaccine. Three weeks after
immunization the mice were challenged intranasally with
100MLD50 of influenza A/PR/8/34 (Figure 3). In contrast to the
weak effects observed after i.m. immunization, the species D
vaccines were as potent as the species C vaccines in
protecting against influenza when delivered intranasally (Figure
3A and B). There were no detectable differences in protection
induced by either the species C or D Ad vaccines at this dose
and both species of Ad vaccines protected 100% of animals
against death. In addition, both species C and D Ad vaccines
prevented influenza-induced weight loss and disease. A HI
assay on sera from mice immunized intranasally showed
higher HI antibody titers in species D vaccinated mice (Figure
3C). In this case, Ad48 had statistically higher HI titers than
both Ad5 and Ad6 (p = <0.05).
Dose Titration Of Replication-competent Species C And
D Vaccines
The initial vaccine comparisons used high doses of 1010 vp of
the adenoviruses (Figures 2 and 3). To better determine the
relative efficacy of the vaccines by i.n. immunization, a dose
titration of each of the vaccines was performed. BALB/c mice
vaccinated with 109 vp/mouse showed no signs of weight loss
and had 100% survival (Figure 4). Lower doses of 107 vp/
mouse allowed weight loss and death in all vaccinated groups.
No protection was observed doses of 106 vp/mouse (Figure 4).
The Ad28 vaccine was the most effective of the species D
vaccines and provided complete protection against disease
and death at a dose of 108 vp/mouse (Figure 4B). Ad26 and
Figure 1.  Comparison of cross-protection by monovalent 2009 H1N1 vaccine (MIV) vs. Ad expressing 2009 H1N1 HA (Ad-
TX).  Groups of 5 BALB/c mice were immunized intramuscularly with either the MIV (A) or the Ad-TX vectored vaccine (B) at the
indicated vaccine doses and then challenged intranasally with A/PR/8/34. Weight loss and survival was monitored. There were no
cross-protective immune responses induced in the MIV immunized mice and all mice were sacrificed due to weight loss by day 7.
However, 100% of mice immunized with ≥108 viral particles (75 ng) of Ad-TX had cross-protective immune responses and were
completely protected from death.
doi: 10.1371/journal.pone.0073313.g001
Species D Adenovirus Flu Vaccines
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Ad48 vaccinated mice showed lost weight and only 80%
survived at a dose of 108 vp/mouse (Figure 4 A and C).
Dose Titration of Replication-defective Ad Vaccines
The replication-competent vaccines have the potential to
replicate their genomes up to 10,000-fold to amplify antigen
expression. To compare these to more traditional replication-
defective Ad vaccines, replication defective Ad28 (Ad28-RD)
and replication-defective Ad5 (Ad5-RD) expressing the same
hemagglutinin were tested by the intranasal route (Figure 5).
With these vectors, mice that were immunized with 108 vp/
mouse of Ad28-RD showed some weight loss. At 108 vp/
mouse, Ad5-RD (Figure 5A) showed more weight loss than
Figure 2.  Vaccine efficacy of species C and D Ad vectors by high dose systemic immunization.  Groups of 5 BALB/c mice
were administered 1010 viral particles of the indicated vectors intramuscularly. All viral vectors contained a transgene cassette that
expressed a soluble hemagglutinin (HA) derived from the influenza strain A/PR/8/34. Three weeks after immunization the mice were
anesthetized i.p. with ketamine (140 mg/kg)/xylazine (5.55 mg/kg). The mice were challenged intranasally with 100MLD50 of
influenza A/PR/8/34. The mice were weighed for baseline measurements. Included in the sacrifice criteria was 25% body weight
loss.
doi: 10.1371/journal.pone.0073313.g002
Species D Adenovirus Flu Vaccines
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Ad28-RD (Figure 5B). There was no protection in either group
vaccinated with a dose of 106 vp/mouse.
Vaccine Efficacy in the Presence of Pre-existing
Immunity to Adenovirus
Many vaccines need to be delivered at least two times for
priming and boosting. To model this situation, mice were
immunized intramuscularly with 1010 vp/mouse of Ad28
expressing GFPLuc. Sera were collected 6 weeks after
immunization and tested for anti-Ad26 and anti-Ad28
neutralizing antibodies (Figure 6A). All immunized mice had
high levels of Ad28 neutralizing antibodies (NAbs) but
undetectable levels of Ad26 NAb. The mice were then
vaccinated against influenza by intranasal administration of
1010 vp/mouse of Ad28-PR or Ad26-PR expressing the
Figure 3.  Vaccine efficacy of species C and D Ad vectors by high dose mucosal immunization.  Groups of 5 BALB/c mice
were administered 1010 viral particles of the indicated vectors intranasally. All viral vectors contained a transgene cassette that
expressed a soluble hemagglutinin (HA) derived from the influenza strain A/PR/8/34. Three weeks after immunization the mice were
anesthetized i.p. with ketamine (140 mg/kg)/xylazine (5.55 mg/kg). The mice were challenged intranasally with 100MLD50 of
influenza A/PR/8/34. The mice were weighed for baseline measurements. Included in the sacrifice criteria was 25% body weight
loss.
doi: 10.1371/journal.pone.0073313.g003
Species D Adenovirus Flu Vaccines
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influenza A/PR/8/34 HA (Figure 6B and C). The mice were
challenged intranasally with 100MLD50 of influenza A/PR/8/34
three weeks after the second immunization. In the face of prior
Ad28 immunity, mice that were immunized with either Ad26-PR
or Ad28-PR suffered slight weight loss (Figure 6B), but all
survived the challenge (Figure 6C).
Vector-Induced Innate Immunity
Some studies have shown that innate immunity to empty
Ad5-ΔE1/E3 virus could confer non-specific protection against
influenza by innate immunity [30]. In order to rule out protection
by innate immunity, groups of 5 mice were immunized
intranasally with 1010 vp of Ad26 expressing the vaccine
transgene or an irrelevant transgene (GL). Groups of mice
were challenged with 100 MLD50 of influenza A/PR/8/34 3 days
and 3 weeks post-immunization with vectors expressing
GFPLuc. When mice were challenged 3 days post-
immunization there was no change in weight loss and survival
as compared to the control group (Figure 7A). Mice that were
challenged 3 weeks post-immuization also showed significant
Figure 4.  Dose titration of species D replication-competent Ad vectored vaccines.  Groups of 5 BALB/c mice were immunized
intranasally with 10-fold dilutions of vaccine from 109 vp/mouse to 106 vp/mouse. All viral vectors contained a transgene cassette
that expressed a soluble hemagglutinin (HA) derived from the influenza strain A/PR/8/34 in place of the E3 genes. Mice were
immunized with either species D Ad26 (A), Ad28 (B) or Ad48 (C). Three weeks after immunization the mice were anesthetized i.p.
with ketamine (140 mg/kg)/xylazine (5.55 mg/kg). The mice were challenged intranasally with 100MLD50 of influenza A/PR/8/34. The
mice were weighed for baseline measurements. Included in the sacrifice criteria was 25% body weight loss.
doi: 10.1371/journal.pone.0073313.g004
Species D Adenovirus Flu Vaccines
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weight loss and mortality as compared to the control group
(Figure 7B). Ultimately, there were no differences in weight loss
or survival in the immunized groups regardless of transgene,
as compared to control DPBS immunized mice (Figure 7)
Therefore, it is highly unlikely that innate immunity plays any
role in the protection provided by species D Ad vectored
vaccines. In addition, mice immunized with Ad26-PR and
challenged at 3 days post-immunization were not protected
against a lethal influenza challenge. However, mice that were
challenged at 3 weeks post-immunization were protected
(Figure 3). This suggests that a resting period is a necessity for
the maturation of a protective immune response.
Discussion
The philosophy of influenza virus control by vaccination has
recently come under high levels of scrutiny. There have been
numerous mismatches in vaccine formulations in the last
decade that resulted in a lack of protective immunity. Influenza
surveillance in Asia and Australia is used to predict which
influenza strains might spread in the USA. While this is
generally effective, these predictions can fail [4,31,32]. In fact,
the accuracy of WHO recommended strains and those strains
causing outbreaks was only 77% between 1987 and 1997 [33].
Put another way, influenza strain predications have failed 23%
of the time leaving humans unprotected against seasonal and
potentially pandemic influenza. The degree of vaccine
mismatch from the 2009 pandemic Swine flu could not have
been greater. The genetic distance between the vaccine strain
and the pandemic strain was an impressive 20.5% based on
the HA amino acid analysis. This is very alarming considering
that there is only ~21% amino acid divergence in all of the H1
HA strains. It took 8 to 9 months for the first large-scale 2009
swine flu vaccine to become available and by that time the first
wave of the pandemic influenza outbreaks had passed [34].
Most people would agree that this is unacceptable. In addition
Figure 5.  Dose titration of species C and D replication-defective Ad vectored vaccines.  Groups of 5 BALB/c mice were
immunized intranasally with 10-fold dilutions of vaccine from 109 vp/mouse to 106 vp/mouse. All viral vectors contained a transgene
cassette that expressed a soluble hemagglutinin (HA) derived from the influenza strain A/PR/8/34 in place of the E1 genes. Mice
were immunized with either replication-defective species C Ad5-RD (A) or replication-defective species D Ad28-RD (B). Three
weeks after immunization the mice were anesthetized i.p. with ketamine (140 mg/kg)/xylazine (5.55 mg/kg). The mice were weighed
for baseline measurements. Included in the sacrifice criteria was 25% body weight loss. The mice were challenged intranasally with
100MLD50 of influenza A/PR/8/34.
doi: 10.1371/journal.pone.0073313.g005
Species D Adenovirus Flu Vaccines
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to the vaccine mismatches and failure to effectively control the
recent 2009 swine flu pandemic, there is still the threat of “bird
flu”, or H5N1 and H7N9. Scientists have published two
research articles in which minor mutations in the HA gene
could convert the bird flu to a form that was droplet
transmissible in mammals [35,36]. The mortality rate in humans
infected with H5N1 is greater than 50% and this coupled with
the inevitability of future pandemics is plenty of cause for action
to investigate alternatives to our current vaccine strategies.
In this study, we have demonstrated the strength of an Ad
vectored vaccine. In a head to head comparison the Ad
vaccine was capable of inducing cross-protective immunity
while the traditional vaccine was not, even at a dose 375 times
the human equivalent. This comparison indicates that Ad
Figure 6.  Vaccination in the presence of Anti-Vector Immunity.  Pre-exisiting immunity was established by immunizing mice
with Ad28 expressing GFPLuc. The sera was collected 6 weeks later and analyzed for anti-Ad26 and anti-Ad28 neutralizing
antibodies (A). The mice were divided into two groups of 5 mice and immunized with either Ad26-PR or Ad28-PR influenza vaccines
expressing the A/PR/8/34 HA. The mice were challenged intranasally with 100MLD50 of influenza A/PR/8/34. The mice were
monitored for signs of disease and weighed daily (B). The mice were euthanized if the percent weight loss exceeded 25% of the
baseline level (C).
doi: 10.1371/journal.pone.0073313.g006
Species D Adenovirus Flu Vaccines
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vectored vaccines may have much higher “take” rates than
traditional vaccines, are capable of inducing cross-protective
immunity and may be robust enough to induce protective
immunity in the elderly and immunocompromised.
A dose titration of the species C and D vaccines showed
similar results. In addition, there were no significant differences
between the replication defective forms of species C and D
vaccines. The inability of species D Ad vaccines to induce
protective immunity when delivered intramuscularly can be
explained by the lack of CD46 in mouse muscle. Species D
Ads use human CD46 as the primary receptor for virus entry.
Mice do not express this receptor. Therefore the lack of CD46
can account for the reduced transduction of the muscle.
However, the D Ad vaccines were effective when delivered
intranasally suggesting the presence of a functional mouse
CD46 homolog or the use of a secondary receptor that is also
not present in the muscle. We have found that species D Ad
vectors are capable of transducing CD46 transgenic mice
intramuscularly equally well as compared to the species C Ad5
vectors (data not shown). We propose that vaccine studies
using these transgenic mice will provide a more accurate
evaluation of their vaccine efficacy. If these Ad D vaccines are
transducing via a secondary receptor intranasally, the
restoration of the CD46 receptor may allow for even greater
levels of transduction that results in the induction of protection
at much lower doses than this study indicates.
The vaccine immunogen used in these studies, HA from
A/PR/8/34, was modified to have a deletion of the cleavage,
fusion and transmembrane domain (HA-ΔCFT). This was done
in order to create a secreted protein that was resistant to
proteolytic cleavage so that it would remain intact. We
hypothesized that an intact secreted HA would induce greater
humoral immunity. However, upon characterization we found
that the full-length version was capable of generating protective
immune responses at a lower dose. Dose response studies
using Ad5 expressing the full-length A/PR/8/34 gene showed
complete protection at 107 vp/mouse [28]. However, the soluble
Figure 7.  Induction of protection by innate immunity.  Groups of 5 BALB/c mice were immunized intranasally with 1010 vp of
wildtype Ad26 (Ad26 wt), replication-competent Ad26 expressing the PR HA or the eGFPLuc fusion gene (Ad26ΔE3-PR and
Ad26ΔE3-GL, respectively) and a replication-defective Ad26 expressing the eGFPLuc fusion gene (Ad26ΔE1-GL). In order to
identify vector-induced early non-specific innate immunity, the mice were challenged 3 days post-immunisation with 100MLD50 of
influenza A/PR/8/34 (A). In order to identify vector-induced late non-specific innate immunity, the mice were challenged 3 weeks
post-immunisation with 100MLD50 of influenza A/PR/8/34 (B). The mice were weighed for baseline measurements. Included in the
sacrifice criteria was 25% body weight loss. All immunized mice had significant weight loss and mortality regardless of the
expressed transgene or vector platform. There were no statistically significant differences in between groups or control DPBS mice
at either time point.
doi: 10.1371/journal.pone.0073313.g007
Species D Adenovirus Flu Vaccines
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form of HA required a dose of 109 vp/mouse for complete
protection against morbidity.
In order to determine if a species D Ad vaccine could be
effective in the presence of pre-existing immunity, we
established anti-Ad neutralizing antibodies by immunizing with
Ad28 expressing GFPLuc. We tested the sera at 6 weeks post-
immunization and found high anti-Ad28 neutralizing antibodies.
We found that mice that had high levels of pre-existing
immunity against Ad28 could still be protected against a lethal
influenza challenge using a homologous Ad28-PR vaccine.
This is promising since it demonstrates an effective ability to
reuse the same vaccine even in the presence of high anti-
vector immunity. One caveat to this observation is that the
second immunization with the homologous Ad28-PR vaccine
was at a high dose of 1010 vp/mouse. This dose may be too
much to be effectively translated to a human dose equivalent.
Further studies will determine if the vaccine dose could be
titrated down to a more usable dose.
In this study we have investigated the use of species D Ad
viral vectors as vaccines for influenza. One of the biggest
advantages of using these viral vectors over other Ad species
is that they have a low seroprevalence in humans. In addition,
they exhibit low levels of pathogenicity, can be isolated from
asymptomatic patients, and are not associated with any known
severe disease. Importantly, we have shown that the route of
immunization is critical when using species D Ad vaccines. The
species D vaccines were more than 100-fold more effective
when delivered mucosally. This is an important find since other
researchers are investigating the use of species D Ad vaccines
as well as other non-human primate Ad vaccines for use
against HIV [37–41]. In addition, cloning the entire viral
genomes into a single plasmid allows us to rapidly create
recombinant viruses. We propose that, due to the findings in
this study, these viral vectored vaccines could be an important
alternative to the currently used TIV and FluMist vaccines and
warrant further investigation.
Materials and Methods
Ethics Statement
Female BALB/c mice (6-8 weeks old) were purchased from
Charles River Laboratories (Wilmington, Massachusetts, USA)
and housed in the Mayo Clinic Animal Facility under the
Association for Assessment and Accreditation of Laboratory
Animal Care (AALAC) guidelines with animal use protocols
approved by the Mayo Clinic Animal Use and Care Committee
(protocol A110). All animal experiments were carried out
according to the provisions of the Animal Welfare Act, PHS
Animal Welfare Policy, the principles of the NIH Guide for the
Care and Use of Laboratory Animals, and the policies and
procedures of Mayo Clinic.
Adenovirus vaccine production
In order to create new recombinant adenoviral vectors the
genomes of Ad6, Ad26, Ad28 and Ad48 were cloned
individually into a single low copy plasmid. The Ad5 vaccine
was generated using the stratagene shuttle plasmids as
previously described [42]. The E1 or E3 genes of the cloned
adenoviral vectors were replaced with an expression cassette
that expressed a hemagglutinin (HA) from A/PR/8/34 that was
modified to have a deletion of the cleavage, fusion and
transmembrane domain (HA-ΔCFT). Replication competent Ad
vaccines were generated by replacing the E3 genes and
replication defective versions were made by replacing the E1
genes. All of the viruses were rescued and amplified in 293
cells. Cell factories (Corning, Rochester, NY, USA) were used
for large-scale preparations. The final virus preps were purified
on two sequential CsCl ultracentrifuge gradients, desalted
using Econopac® 10-DG chromatography columns (Bio-Rad,
Herculaes, Ca, USA), resuspended in KPBS (1.0 M Sucrose)
and stored at -80°C. The final concentrations were determined
by OD260.
Wild-type Adenovirus and gDNA purification
Wild-type (wt) Ad6 strain Tonsil 99 (ATCC VR-1083), Ad26
strain BP-2 (ATCC VR-224), Ad28 strain BP-5 (ATCC VR-226),
and Ad48 strain T85-884 (ATCC VR-1406) (American Type
Culture Collection, Manasses, VA, USA) were amplified in low
passage 293 cells (Microbix Biosystems Inc., Toronto, Ontario,
Canada). Viral genomic DNA (gDNA) was purified using a
PureLink™ Viral RNA/DNA Mini Kit (Invitrogen, Carlsbad, CA,
USA).
Generation of Species C Adenoviral Type 6 Vector
The left and right arms of the Ad6 gDNA were amplified by
PCR using Platinum Taq Supermix High Fidelity (Invitrogen,
Carlsbad, CA, USA). A unique SgfI restriction enzyme site was
added just outside of the left and right ITRs. The following
primers were used to amplify the PCR product: Ad6 SgfI ITR
(5’-
GCGATCGCCATCATCAATAATATACCTTATTTTGGATTG-3’),
Ad6 Cla1 R (5’-
GGGGGCTGTAATGTTGTCTCTACGCCTGCACATAATCTAA
CACAAACTCCTCACCCTC-3’) and Ad6 AvrII F (5’-
GAGGGTGAGGAGTTTGTGTTAGATTATGTGCAGGCGTAGA
GACAACATTACAGCCCCC-3’). The 3’ end of Ad6 Cla1 R
contained 28 nucleotides (nt) of homology to the right arm of
the Ad6 gDNA from nt 35,208 to 35,235 and the 5’ end of Ad6
AvrII F contained 30 nt of homology to the left arm of the Ad6
gDNA from nt 979 to 1,008 (Figure S1A). The two PCR
products were then joined using an overlapping PCR reaction.
One µl of each PCR product and 2 µl of 10µM primer Ad6 SgfI
ITR were added to 45 µl of Platinum Taq Supermix High
Fidelity and extended (Figure S1B). The overlapping PCR
product was cloned into TOPO PCR 2.1 (Invitrogen, Carlsbad,
CA, USA). The Kanamycin resistance gene (KANR) and the
pBR322 origin of replication (pBR322 ori) from Ad-Easy
(Stratagene) was PCR amplified using Platinum Taq Supermix
High Fidelity and cloned into TOPO-XL (Invitrogen, Carlsbad,
CA, USA) using the following primers: Kan ori SgfI-F (5’-
GCGATCGCTAATTAACATGCATGGATCCATATGCGGTGTG-
3’) and Kan ori SgfI-R (5’-
GCGATCGCTTAATTAAGAATTAATTCGATCCTGAATGGCGA
ATGG-3’) (Figure S1C). The KanR and pBR322 ori were ligated
to the overlapping PCR using PvuI sites to form the cloning
plasmid, pAd6-cloner (Figure S1D). Ad6 gDNA and pAd6-
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cloner were digested with ClaI and AvrII, separated on a TAE
agarose gel containing 17.5 µg/ml Crystal Violet, and purified
using a S.N.A.P.™ Gel Purification Kit (Invitrogen, Carlsbad,
CA, USA). The ClaI/AvrII gDNA fragment (Figure S1E) and the
ClaI/AvrII digested pAd6-cloner were ligated to form the pAd6
ClaI/AvrII plasmid (Figure S1F). Finally, the AvrII digested
gDNA fragment was ligated into the pAd6 ClaI/AvrII plasmid
that was digested and purified as previously described to form
the final construct, pAd6 (Figure S1G). The final construct was
checked by RE digestion to confirm correct orientation,
digested with SgfI, and desalted using a QIAexII purification kit
(Qiagen, Valencia, CA, USA). The SgfI digested pAd6 was
transfected into 293 cells using Polyfect (Qiagen, Valencia, CA,
USA) and wt Ad6 virus was rescued.
Generation of Species D Adenoviral Vectors
We have cloned the genomes of three species D Ads types
26, 28 and 48 into single low copy plasmids for use in creating
recombinant adenoviruses. All of the viral genomes were
cloned using similar strategies as previously described for Ad6.
Briefly, for Ad26, two overlapping PCR products that were
designed to extend into the 5’ and 3’ ends of the genome. The
PCR products extended to the EcoRI sites (Figure S2A). To
clone the Ad26 viral genome the following primers were used
to amplify the right and left sides of the Ad26 genome with
overlapping homology designed into the primers: Ad26 ITR-
PacI 5’-
ATTTAATTAACATCATCAATAATATACCCCACAAAGTAAACA
AAAG, Ad26-Clone Frag-F 5’-
AATGAGAGCAGGAGTGATGAATATGAATTCTATTACCATCT
TCGTCCCTTAGCAA, Ad26-Clone Frag-R 5’-
TTGCTAAGGGACGAAGATGGTAATAGAATTCATATTCATCA
CTCCTGCTCTCATT. The two overlapping PCR products were
used to create a final full-length PCR product that fused the two
PCR fragments together at the EcoRI site (Figure S2A). The
primers used to create the fused PCR product were also
designed to contain unique PacI 5’ restriction sites so that the
captured genomes can be released from the plasmid for rescue
in mammalian cells (Figure S2B). The fused overlap PCR
products were cloned into TOPO-pCR2.1-TOPO (Invitrogen,
Carlsbad, CA) and verified by sequencing. Next, the a plasmid
backbone containing a low copy origin of replication (pBR322)
and kanamycin resistance gene was PCR amplified using
primers that contain 5’ and 3’ PacI restriction sites (Figure
S2C). Figure S2D shows the final cloning plasmid. The Ad26
genomic DNA and the cloning plasmid were digested with
EcoRI (Figure S2E). The cloning plasmid was
dephosphorylated with Antarctic phosphatase and gel purified.
The digested gDNA and cloning plasmid were mixed at a 3:1
insert to vector ratio and ligated overnight at 4C. The ligation
mixture was used to transform electrocompent XL-1 blue cells
and colonies were selected on Kanamycin LB plates.
Miniprepped DNA was digested to confirm the capture of the
EcoRI Ad26 gDNA in the correct orientation (Figure S2F). For
Ad28, the unique restriction enzyme site EcoRI and NheI were
used to capture the genome (Figure S3A and E). To clone the
Ad28 genome the following primers were used to amplify and
fuse the right and left side of the Ad28 genome: Ad28 F 5’-
TGGGGTGCTGTTCATGGCCAACAGCCAAAGCTAGCACCC
AAAAACTGCACGCT, Ad28 R 5’-
AGCGTGCAGTTTTTGGGTGCTAGCTTTGGCTGTTGGCCAT
GAACAGCACCCCA and Ad28 ITR PacI 5’-
TTAATTAACATCATCAATAATATACCCCAC. Figure S3F
shows the final cloned Ad28 gDNA plasmid. For Ad48, the
EcoRI and MluI sites were used to capture the genome (Figure
S4A and E). To clone the Ad48 genome the following primers
were used to amplify and fuse the right and left side of the
Ad48 genome: Ad48 PacI F1 5’-
ATTTAATTAACATCATCAATAATATACCCCACAAAGTAAACA
AAAGTTAATATGC, Ad48 R 5 prime 5’-
GCGTAGAGCCACTGCTCGAAGCCACAGATGAAGATCATG
GAATTCATATTCATCA, and Ad48 F 3 prime 5’-
TGATGAATATGAATTCCATGATCTTCATCTGTGGCTTCGAG
CAGTGGCTCTACGC. Figure S4F shows the final cloned
Ad48 gDNA plamid.
Recombinant Adenoviral Vectors
Shuttle plasmids were generated to transfer genes into each
of the cloned adenovirus genomes by recombination in bacteria
(Figure S5). These shuttle plasmids are composed of an
expression cassette containing a secretable intact HA gene
driven by the cytomegalovirus enhancer/promoter that is
adjacent to the zeocin antibiotic resistance marker. Both the
transgene and selective marker are flanked by homologous
sequence of the adenovirus region that will be recombined.
The following briefly describes how the shuttles were
constructed. First, primers were designed to produce an
overlapping PCR product containing a unique AscI site
between the overlapping products (Figure S5A and C). The
overlapping PCR products were designed to amplify ~500
nucleotides of the regions outside the area specified for
recombination. The two PCR reactions were combined and
extended to produce a fused PCR product containing a unique
AscI site between the two homology regions flanked by PmeI
sites (Figure S5B and C). The transgene was prepared by
cloning the transgene into a CMV-PolyA expression cassette
(e.g. CMV-GFPLuc-PolyA). The selection marker containing
the EM7 promoter and zeocin resistance gene gene were
amplified with homology to the transgene expression cassette
5’ to the PolyA and recombined into the plasmid using the red
recombinase system [43]. The zeocin gene was flanked by
FRT sites to facilitate removal by FLP recombinase at a later
time point if needed (Figure S5D). Next, the entire expression
cassette with selection marker was amplified using primers with
AscI sites engineered into the 5’ and 3’ ends. This PCR product
was cloned into the Topo pCR8 cloning plasmid to create the
plasmid pCR8-AscI-GFPLuc-FZF-AscI. The plasmid was
sequence verified. The final shuttle plasmid for recombination
into the adenoviral genome was created by cloning the AscI
digested insert from pCR8-cdE3-AscI-GFPLuc-FZF-AscI into
the plasmid containing the overlapping PCR product at the AscI
sites (Figure S5E). These shuttle plasmids were digested with
PmeI (Figure S6A) and recombined into the complete Ad
genome plasmid using in vivo recombination in BJ5183
competent cells (Figure S6B) to generate the final vector (e.g.
pAd26-dcE3-PR-dCFT-FZF plasmid) (Figure S6C). The final
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recombined plasmids were subcloned in XL-1 cells and
plasmid DNA was amplified and purified using a Qiagen
HiSpeed Maxiprep kit.
The modified viral genomes were digested from their plasmid
backbones using PacI and transfected into 293 cells. The
rescued virus was amplified and purified on two sequential
CsCl gradients.
Adenovirus immunization
Mice were anesthetized by intraperitoneal (i.p.) injection with
ketamine (140 mg/kg)/kylazine (5.55 mg/kg) and were
immunized by intramuscular (i.m.) or intranasal (i.n.) routes.
Mice immunized by the i.m. route received the Ad vaccine or
the monovalent inactivated virus (MIV) H1N1 2009 (BEI
Resources) in two 25 µl injections into each quadricep muscle
(50 µl total volume). Mice immunized by the i.n. route received
the Ad vaccine in two 10 microliter instillations into each nare
(20 µl total volume).
Hemaglutination Inhibition (HII) Assay
The HI assay was performed as previously described [28].
Briefly, Groups of 5 BALB/c mice were immunized i.m. and i.n.
with 1010 vp/mouse of adenovirus expressing the HA-∆CFT
codon-optimized gene from influenza A/PR/8/34. The mice
were bled three weeks post-immunization and serum was
separated using Becton Dickinson microtainer tubes. Two-fold
dilutions of sera in 50 microliters of DPBS were added to a 96-
well, nonsterile, nontissue culture–treated, round bottom
microtiter plate. Four hemagglutinating units (HAU) of influenza
virus in 50 µl was added to the diluted sera and incubated at
room temperature (RT). After 1 hr., 50 µl of a 1.0% chicken
RBC solution was added and incubated at RT for 1 hr. The HI
titer was determined to be the highest serum dilution to inhibit
hemagglutination.
Influenza challenge
Mice were challenged intranasally three weeks after
immunization. The mice were anesthetized and challenged with
100 MLD50 (50% mouse lethal doses) of mouse adapted
influenza virus A/PR/8/34 by two 10 microliter instillations into
each nare (20 µl total volume). The mice were observed for
morbidity and weight loss over subsequent days and were
euthanized if weight loss reached 25% of initial body weight.
Adenovirus Neutralization Assay
Groups of mice were immunized intramuscularly with 1010 vp/
mouse of Ad28 expressing the eGFP/Luciferase fusion protein.
Six weeks post immunization the mice were bled by the
submandibular method and the sera was tested for anti-
adenovirus neutralizing antibodies (NAbs). NAbs were
determined as previously described [44]. Briefly, sera were
heat inactivated at 56°C for 30 min before a serial 2-fold
dilution was performed in a 96 well black plate (3603 Corning).
Sera were diluted from 1/20 to 1/2560 in a volume of 50 µl of
cDMEM containing 1 X 108 Ad-GL vp/ml. Naïve mouse serum
was used as negative controls and was the maximum
luciferase activity reference. The plates were incubated at 37°C
for 1 h. Fifty µl of A549 cells at 1 X 105 cells/ml was added to
each well and the plates were incubated for 20 h at 37°C and
5% CO2 before readout. The luciferase activity was determined
using the reporter lysis 5X buffer and luciferase assay reagent
(LAR) (Promega, Madison, WI) as described by the
manufacturer protocol. Briefly, 25 µl of 5X lysis buffer was
added to each well, mixed and frozen at -80C. The plates were
thawed at RT and 50 µl of LAR was added. The plate was
shaken on an orbital shaker and luciferase activity was
measured using a Beckman Coulter DTX 880 Multimode
Detector. Neutralizing antibodies titers were determined as the
reciprocal dilution to inhibit 50% of luciferase activity as
compared to no serum controls and are expressed as the
geometric mean titer (GMT).
Statistical Analyses
Data was evaluated using GraphPad Prism 4 software.
Unpaired, two-tailed TTests, ANOVA with Bonferroni post test
and Log-rank (Mantel-Cox) tests were used to determine
statistical significance. P values ≤ 0.05 were considered
statistically significant.
Supporting Information
Figure S1.  The cloning strategy for Adenovirus type 6.
An overlapping PCR product that fuses the left and right
regions of the Ad6 genome at the ClaI and AvrII restriction sites
(A and E). This PCR product was ligated to the low copy origin
of replication and kanamycin resistance gene (C) to create the
cloning plasmid (D). The genomic DNA of Ad6 is digested with
Cla I and AvrII and ligated into the pAd26 cloner to create the
pAd6 ClaI/AvrII plasmid (F). The AvrII genomic fragment was
then ligated in to create the pAd6 gDNA correct plasmid (G).
(TIFF)
Figure S2.  The cloning strategy for Adenovirus type 26.
An overlapping PCR product that fuses the left and right
regions of the Ad26 genome at the unique EcoRI restriction site
(A and E) was ligated to the low copy origin of replication and
kanamycin resistance gene (C) to create the cloning plasmid
(D). The genomic DNA of Ad26 is digested with EcoRI and
ligated into the pAd26 cloner to create the plasmid pAd26
gDNA correct (F).
(TIFF)
Figure S3.  The cloning strategy for Adenovirus type 28.
An overlapping PCR product that fuses the left and right
regions of the Ad28 genome at the unique EcoRI and NheI
restriction sites (A and E) was ligated to the low copy origin of
replication and kanamycin resistance gene (C) to create the
cloning plasmid (D). The genomic DNA of Ad28 was digested
with EcoRI and NheI (E). The digested genomic DNA was
ligated into the pAd28 cloner plasmid to create the plasmid
pAd28 complete 4.5Kb kan ori (F).
(TIFF)
Figure S4.  The cloning strategy for Adenovirus type 48.
Species D Adenovirus Flu Vaccines
PLOS ONE | www.plosone.org 12 August 2013 | Volume 8 | Issue 8 | e73313
An overlapping PCR product that fuses the left and right
regions of the Ad48 genome at the unique EcoRI and MluI
restriction sites (A and E) is ligated to the low copy origin of
replication and kanamycin resistance gene (C) to create the
cloning plasmid (D). The genomic DNA of Ad48 was digested
with EcoRI and ligated into the pAd48 cloner to create the
plasmid pAd48 gDNA correct (F).
(TIFF)
Figure S5.  Construction of shuttle plasmids to modify
Adenoviral genomes.
First, primers are designed to produce an overlapping PCR
product that contains a unique AscI site between the
overlapping products (A). The overlapping PCR products are
designed to amplify the regions outside the area specified for
recombination (C). To illustrate this design we used the Ad26
E3 deletion shuttle plasmid. 500 nucleotides of both the Ad26
17.5K and 14.7K gene were PCR amplified with primers with
homology designed into the 3’ end of the 17.5K product and
the 5’ end of the 14.7K product. The two PCR reactions were
combined and extended to produce a fused PCR product (B).
The final fused PCR product was designed to possess a
unique AscI site between the two PCR product (B). The Ad26-
dE3-PCR-AscI-PmeI PCR product was cloned into the Topo-
pCR8 cloning plasmid and sequenced. The transgene was
prepared by cloning the transgene (HA-∆CFT) into a CMV-
PolyA expression cassette (D). To insert the selection marker,
the EM7 promoter and zeocin gene were PCR amplified with
homology to the transgene expression cassette 5’ to the PolyA.
The zeocin gene was flanked by FRT sites to facilitate removal
by FLP recombinase at a later time point if needed. Next the
entire expression cassette and the selection marker was
amplified using primers designed with AscI sites engineered
into the 5’ and 3’ ends (D). The final plasmid, pCR8-Ad26-dE3-
HA-dCFT-FZF was created by cloning the AscI flanked
transgene into the shuttle plasmid for recombination into the E3
region.
(TIFF)
Figure S6.  Recombination into the Adenoviral gDNA.
The shuttle plasmid was digested with PmeI (A) and
cotransfected into BJ5183 cells to recombine into the complete
Ad26 genome plasmid (B). The final recombined pAd26-dcE3
PR-dCFT-FZF plasmid was transformed into XL-1 cells and
maxiprepped (C).
(TIFF)
Figure S7.  Analysis of HA expression by recombinant
Adenoviral Vectors.
293 and A549 cells were infected with 1000 vp/cell with each of
the Ad-HA expressing viruses. The cells were harvested at
24h. Lysates from the infected cells were electrophoresed and
transferred to PVDF membranes. After blocking, the
membranes were probed with polyclonal anti-HA donkey sera
(BEI Resources) and monoclonal anti-actin-HRP (I-19, Santa
Cruz Biotechnology). The anti-HA donkey antibody was
detected by rabbit anti-donkey-HRP (BioRad). After washing,
the blot was developed using Super Signal West Dura
substrate and imaged using a Kodak In Vivo F Imaging
detector. Densitometry was performed using the Kodak
Molecular Imaging Software v 4.0.4.
(TIFF)
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